Q-omics provides the consensus-scored PROP1 profile across patient tissues and cancer cell-line models. PROP1 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PROP1 is differentially expressed in 6, with the highest sampling consensus in THCA. Additionally, PROP1 RNA expression shows 8,258 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight KIRC, THCA, and LAML as cancer lineages where PROP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PROP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PROP1 survival associations across molecular data types. PROP1 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PROP1 RNA expression–survival associations across cancer types. High PROP1 expression shows unfavorable associations in KIRC, UCS, TGCT, OV and DLBC, but favorable associations in HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify KIRC as the clearest survival context for PROP1 RNA expression.
This table summarizes PROP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for PROP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PROP1 shows lower tumor expression in THCA and LUAD and higher tumor expression in BLCA, BRCA, CHOL and LIHC. The THCA box plot shows higher PROP1 RNA expression in normal versus tumor tissue (log2 FC = −0.071, t-test p < 0.001).
This table shows molecular features associated with PROP1 in patient tissues and cancer cell lines. In patient samples, PROP1 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set. In cancer cell lines, PROP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in CNS and SKIN.
